Role of autologous bone marrow transplant in multiple myeloma

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 733-741

  Blanes, Margarita ^a,b   De La Rubia, Javier ^a,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

Author keywords

conditioning regimens; consolidation; maintenance; multiple myeloma; transplantation

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONSOLIDATION CHEMOTHERAPY; DISEASE COURSE; HEALTH CARE QUALITY; HEMATOLOGIC DISEASE; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; CONSOLIDATION CHEMOTHERAPY; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MELPHALAN; MULTIPLE MYELOMA; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 84868239865     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328358f686     Document Type: Review

References (65)

1. Moreau P, Avet-Loisseau H, Harousseau JL, Attal M. Current trend in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011; 29:1898-1906.
2. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117:6063-6073.
3. Cavo M, Baccarani M. The changing landscape of myeloma therapy. N Engl J Med 2006; 354:1076-1078.
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-2520.
5. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008; 26:480-492.
6. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009; 145:681-708.
7. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009; 114:5436-5443.
8. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335:91-97.
9. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
10. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13:183-196.
11. Moreau P, Rajkumar SV. Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment? Leuk Res 2012; 36:677-681.
12. Kumar SK, Lacy MQ, Dispenzeri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012; 118:1585-1592.
13. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24:929-936.
14. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92:3131-3136.
15. Facon T, Mary JY, Harousseau JL, et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol. Blood 1996; 88(Suppl. 1):[abstract 685].
16. Boccadoro M, Cavallo F, Nagler A, et al. Melphalan/prednisone/ lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL 200) in newly diagnosed multiple myeloma (MM). J Clin Oncol 2011; 29(Suppl.):[abstract 8020].
17. Ludwig H, Beksac M, Bladé J, et al. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist 2011; 116:388-403.
18. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stemcell transplantation for multiplemyeloma.NEngl JMed2003;349:2495-2502.
19. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25:2434-2441.
20. Segeren CM, Sonneveld P, van der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101:2144-2151.
21. Fermand J. High dose therapy supported with autologous blood stem cell transplantation in multiple myeloma: long term follow-up of the prospective studies of the MAG group. Haematologica 2005; 90(Suppl. 1):[abstract 40].
22. Goldschmidt H. Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial. Haematologica 2005; 90(Suppl. 1):[abstract 38].
23. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 101:100-106.
24. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and the University of Arkansas for Medical Sciences. J Clin Oncol 2010; 28:1209-1214.
25. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet 2010; 376:2075-2085.
26. Moreau P, Attal M, Pégouré B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01.
27. Knop S, Langer C, Engelhardt M, et al. RAD (lenalidomide, adriamycin and dexamethasone) is a novel and very effective induction regimen in newly diagnosed multiple myeloma preceding a risk-adjusted transplant strategy. Blood 2011; 118:[abstract 3967].
28. Sonneveld P, Schmidt-Wolf IGH, Van der Holt B, et al. HOVON-65/GMMGHD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma. Blood 2010; 116:[abstract 40].
29. Morgan G, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destine for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012; 97:442-450.
30. Rosiñ ol L, Cibeira MT, Mateos MV, et al. Results of pre and postautologous stem cell transplantation (ASCT) with three induction regimens in multiple myeloma (MM): superiority of VTD (bortezomib/thalidomide/ dexamethasone) over TD and VBMCP/VBAD plus bortezomib (VBMCP/VBAD/V). Haematologica 2011; 96(Suppl. 1):S69 [abstract 138].
31. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011; 118:5752-5758.
32. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone (CyborD) induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23:1337-1341.
33. Roussel M, Avet-Loiseau H, Moreau P, et al. Bortezomib, lenalidomide and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: updated results of the 2008 phase II VRD intensive program. Blood 2011; 118:[abstract 1872].
34. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119:2100-2105.
35. Jakubowiak AJ, Griffith KA, Reece DE, et al. Lenalidomide, bortezomib, pegylated liposomal, doxorubicin and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 2011; 118:535-543.
36. Khan ML, Reeder CB, Kumar SK, et al. A comparison of lenalidomide/ dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2012; 156:326-333.
37. Mellqvist UH, Gimsing P, Hjertner O, et al. Improve progression free survival with bortezomib consolidation after high dose melphalan: results of randomized phase III trial. Haematologica 2011; 96(S1):s3 [abstract 0-11].
38. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28:2077-2084.
39. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120:9-19.
40. Ludwing H, Durie B, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012; 119:3003-3015.
41. Lokhorst HM, van de Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high dose melphalan followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115:1113-1120.
42. Stewart KA, Trudel S, Bahlis NJ, et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY10 Trial. Blood 2010; 116:[abstract 39].
43. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and metaanalysis. Blood 2012; 119:7-15.
44. Rosiñ ol L, Cibeira MT, Mateos MV, et al. A phase III PETHEMA/GEM randomised trial of posttransplant maintenance in multiple myeloma: superiority of bortezomib. Bone Marrow transplant 2012; 47(Suppl. 1):S527 [abstract 078].
45. McCarthy P, Owzar K, Hofmeister C, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1770-1781.
46. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1782-1791.
47. Moreau P, Attal M, Harousseau JL. New developments in conditioning regimens before auto-SCT in multiple myeloma. Bone Marrow Transplant 2011; 46:911-915.
48. Blanes M, de la Rubia J, Lahuerta JJ, et al. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma 2009; 50:1-7.
49. Kazmi SMA, Sliba RM, Donato M, et al. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 2011; 46:510-515.
50. Faber EA, Loberiza FR, Akhtari M, et al. A retrospective analysis comparing BEAM vs melphalan prior to first autologous peripheral blood hematopoietic stem-cell transplant in newly diagnosed multiple myeloma patients. Blood 2011; 118(Suppl. 21):[abstract 2040].
51. Gasparetto C, Bacon WA, Doan P, et al. High dose BCNU/melphalan preparative regimen doubles event free survival of myeloma patients undergoing autologous transplantation. Blood 2011; 118(Suppl. 21):[abstract 2012].
52. Blanes M, Lahuerta JJ, Gonzá lez JD, et al. Intravenous busulfan plus melphalan as conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-based approach. Bone Marrow Transplant 2012; 47(Suppl. 1): [abstract 478].
53. Dispenzieri A, Wisema GA, Lacy MQ, et al. A phase II study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol 2010; 85:409-413.
54. Rousell M, Moreau P, Hynh A, et al. Intergroupe Francophone de Myeloma (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with the novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myeloma. Blood 2010; 15:32-37.
55. Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose and schedule finding study. Clin Cancer Res 2010; 16:5079-5086.
56. Nishiori T, Ochoa L, Pidala J, et al. A phase II study of bortezomib plus highdose melphalan (Mel/Vel) conditioning for autologous hematopoietic cell transplantation in multiple myeloma. Blood 2011; 118:[abstract 4158].
57. Sharma M, Khan H, Thall PF, et al. A randomized phase 2 trial of preparative regimen of bortezomib, high-dose, arsenic trioxide, and ascorbic acid. Cancer 2012; 118:2507-2515.
58. Huang W, Li J, Li H, et al. High-dose melphalan with bortezomib as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leuk Lymphoma 2012. [Epub ahead of print]
59. Lahuerta JJ, Mateos MV, Martínez-Ló pez J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM200 study. Haematologica 2010; 95:1913-1920.
60. Thompson PA, Prince HM, Seymour, et al. Bortezomib added to high-dose melphalan as pretransplant conditioning is safe in patients with heavily pretreated multiple myeloma. Bone Marrow Transplant 2011; 46:764-765.
61. Nishiori T, Alekshun TJ, Sullivan DM, et al. Bortezomib followed by phase I study of bortezomib in combination with high-dose melphalan as a preparative regimen for hematopoietic cell transplant in patients with primary refractory multiple myeloma or plasma cell leukaemia. Biol Blood Marrow Transplant 2011; 17:S200-S201.
62. Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012; 118:3549-3555.
63. Jimé nez-Zepeda VH, Michael J, Winter A, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012; 18:773-779.
64. Fenk R, Liese V, Neubauer F, et al. Predictive factors for successful salvage high-dose therapy in the patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011; 52: 1455-1462.
65. Saad A, Vesole D, Le-Rademacher J, et al. Second autologous transplants for multiple myeloma (MM) relapse after a prior autologous transplant (AHCT)-a report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood 2011; 118:[abstract 731].